tbuckley/cabot-search huggingface dataset:
Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria
Authors: Dorte Vistisen, Gregers Stig Andersen, Adam Hulman, Frederik Persson, Peter Rossing, Marit Eika Jørgensen
Journal: Diabetes Care (2019)

OBJECTIVE Persons with diabetes but no chronic kidney disease (CKD) and without albuminuria have the same age-related decline in kidney function as the background population. Whether this also applies following moderate loss in kidney function is unknown. We quantified the impact of albuminuria status on the development of estimated glomerular filtration rate (eGFR) trajectories following CKD stage 3 (CKD3) and assessed potential heterogeneous development patterns among the subgroup with normoalbuminuria. RESEARCH DESIGN AND METHODS We used repeated clinical measures during up to 16 years of follow-up in 935 persons with type 1 diabetes and 1,984 with type 2 diabetes. Trajectories of eGFR by diabetes type and albuminuria status following CKD3 were estimated with spline mixed-effects models with adjustment for relevant confounders. Latent class trajectory modeling was used to find distinct patterns of eGFR development in the subgroups with normoalbuminuria. RESULTS Mean annual declines in eGFR for normo-, micro- and macroalbuminuria the first 10 years following CKD3 were 1.9, 2.3, and 3.3 mL/min/1.73 m2 in type 1 diabetes and 1.9, 2.1, and 3.0 in type 2 diabetes, respectively. For normoalbuminuria, two distinct eGFR patterns were found, one with accelerated declining eGFR levels. This specific progression pattern was associated with less use of lipid-lowering treatment, renin-angiotensin system blockers, and other antihypertensive treatment. CONCLUSIONS Our results support a diabetes-dependent decline in kidney function without albuminuria following CKD3, with a subgroup showing a progressive decline. Furthermore, this group seems to be undertreated in terms of cardioprotective and renal protective treatment and suggests that increased attention should be drawn to normoalbuminuric diabetic kidney disease.
Body weight changes in young breast cancer survivors and associated predictors.
Authors: Tal Sella, Zhenying Tan-Wasielewski, Shoshana M. Rosenberg, Philip Daniel Poorvu, Kathryn Jean Ruddy, Shari I. Gelber, Rulla M. Tamimi, Lidia Schapira, Steven E. Come, Jeffrey M. Peppercorn, Virginia F. Borges, Ann H. Partridge, Jennifer A. Ligibel
Journal: Journal of Clinical Oncology (2019)

11574 Background: Weight gain after cancer diagnosis is common in cancer survivors and has been linked to increased treatment toxicity, poor quality of life, and increased risk of second cancers and overall mortality. Young breast cancer (BC) survivors may be especially susceptible to weight changes given the impact of treatments such as chemotherapy and hormonal therapy on menopausal status. Methods: We identified women with Stage 0-III breast cancer diagnosed at ≤40 years (y) between 2006-2016 from a multi-center prospective cohort study. Clinical data including self-reported pre-diagnosis and follow-up weights were obtained using baseline and follow-up patient surveys. Participants missing baseline weight, pregnant at diagnosis/within 1y of diagnosis or with BC recurrence within 1y were excluded; those pregnant or with BC recurrence between 1-3y from diagnosis were excluded from the 3y analysis. Menopausal status at baseline and treatment-related amenorrhea (TRA) in follow-up were defined by self-reported last menstrual period. Factors associated with weight gain (&gt;5%) were evaluated using univariate two-sided Fisher's exact test. Results: At baseline, 1y and 3y post diagnosis, 956, 899 and 687 women were eligible for analysis respectively. Median age at diagnosis was 37y (17 - 40), 65% received endocrine therapy and 74% chemotherapy. Premenopausal status was verified in 94% at baseline. Mean BMI at baseline was 24.4 (SD 5.3) kg/m2; 20% (187/956) were overweight and 12% (116/956) obese. At 1y and 3y, mean BMI increased modestly to 24.7 (SD 5.6) and 24.9 (SD 5.2), respectively with weight gain (&gt;5%) observed in 18% (164/899) and 13% (87/687) respectively. 37% (300/804) and 32% (196/615) of eligible premenopausal subjects experienced TRA at 1y and 3y, respectively. Receipt of chemotherapy, receipt of endocrine therapy and TRA were not associated with weight gain at any timepoint. Conclusions: In this large prospective cohort of young BC survivors, mean BMI increased only modestly over time. Self-reported weight gain was not associated with treatment and not exacerbated by TRA. Further analysis to understand the effects of physical activity and other predictors of weight gain in this population are ongoing.
Highly versatile cell-penetrating peptide loaded scaffold for efficient and localised gene delivery to multiple cell types: From development to application in tissue engineering
Authors: Rosanne M. Raftery, David P. Walsh, Lia Blokpoel Ferreras, Irene Mencía Castaño, Gang Chen, Mark LeMoine, Gizem Osman, Kevin M. Shakesheff, James E. Dixon, Fergal J. O'Brien
Journal: Biomaterials (2019)
Abstract P371: Raising Awareness Leads to High Provider Visits and Blood Pressure Reduction Among Hypertensive Patients in Bangladesh - A Population-Based Cohort Study
Authors: Dewan S Alam, Muhammad A Chowdhury, Ali T Siddiquee, Sonia Pervin, Shyfuddin Ahmed, Louis W Niessen
Journal: Circulation (2013)

Background: Low patient awareness is associated with uncontrolled blood pressure (BP) which is a leading cause of stroke, myocardial infarction, and chronic kidney diseases in low resource settings...
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
Authors: William D Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Jean-Yves Blay, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Christopher W Ryan, David M Thomas, Charles Peterfy, John H Healey, Michiel van de Sande, Heather L Gelhorn, Dale E Shuster, Qiang Wang, Antoine Yver, Henry H Hsu, Paul S Lin, Sandra Tong-Starksen, Silvia Stacchiotti, Andrew J Wagner
Journal: The Lancet (2019)
Abstract 16443: Therapeutic Effect of Prostaglandin D2 Synthase Inhibition in Experimental Autoimmune Myocarditis
Authors: Toshihiro Yamaguchi, Yoshihiro Motozawa, Hidetoshi Kumagai, Masakazu Shinohara, Yuichi Ikeda, Ichiro Manabe, Kosuke Aritake, Yoshihiro Urade, Issei Komuro
Journal: Circulation (2016)

Introduction: Myocarditis is a life-threatening inflammatory cardiac disorder. Virus-triggered autoimmunity is considered to play a key role in the progression of myocarditis, however, detailed mol...
Abstract 12508: Tuning the Heart Rate Recovery For Age
Authors: Nóra Sydó, Tibor Sydó, Karina A Gonzalez Carta, Joseph G Murphy, Béla Merkely, Thomas G Allison
Journal: Circulation (2015)

Introduction: Exercise parameters such as peak heart rate (HR) are generally adjusted for age, whereas HR recovery is generally given as an absolute value: &lt; 13 bpm at 1 minute post-peak exercise being abnormal. Hypothesis: We analyzed a large cohort of patients to determine the impact of age on HR recovery (HRRec) and if the prognostic performance of HRRec is improved by adjustment for age. Methods: Non-imaging exercise tests performed on patients aged 30-79 years from 1993 to 2010 were included. Patients with known cardiovascular diseases were excluded. Patients were assigned to 5 groups according to age: 30-39, 40-49, 50-59, 60-69, and 70-79. Mortality was reported according to HRRec during the first minute of active recovery using Cox regression analysis. Mortality was determined from Minnesota and National Death Indices. Results: 22,643 patients (64 % male) were included. The median HRRec in the age groups with IQR were as follows: 30-39: 20 [15-26]; 40-49: 19 [14-25]; 50-59: 18 [13-23]; 60-69: 15 [10-20]; and 70-79: 11 [6-16]. There were 1566 deaths (6.9%) over a mean follow-up of 11.8 ± 5.0 years. HRRec of 13 would fall at the 17 th percentile for patients 30-39 years old, but this increased to the 20 th , 27 th , 40 th , and 60 th percentiles with increasing age group. The mortality in age groups according to HRRec is shown in the Figure. For age groups 30-39 and 40-49, the hazard ratio for mortality at a HRRec of 11-12 bpm (i.e. just below the standard of 13) versus patients with a HRRec of ≥ 20 bpm was &gt; 2.0. For age 50-59 and 60-69, however, a HRRec of &lt; 11 bpm is necessary to obtain a doubling of risk, and for age 70-79 a HRRec of &lt; 9 bpm is necessary. Conclusions: HRRec decreases significantly with age. The performance of abnormal HRRec defined as &lt; 13 bpm is inconsistent across age groups. To standardize the ability of HRRec to identify at least a 2.0-fold increased risk, lowering the cup-point to &lt; 11 bpm for ages 50-59 and 60-69 and &lt; 9 bpm for age 70-79 is required.
PF725 REAL WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB
Authors: A. Qiu, S. Shapouri, E. Drill, J. Schade, A. Ravelo, A. Ni, T. Tu‐My, K. Dawson, M. Matasar
Journal: HemaSphere (2019)

Background: Rituximab (R), available as an intravenous (IV; R‐IV) infusion or subcutaneous (SC; R‐SC) injection, is used in the treatment of follicular lymphoma (FL), diffuse large B‐cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). Aims: This study evaluated real‐world practice efficiency changes associated with the adoption of R‐SC by studying differences in chair time by route of administration. Methods: We conducted a retrospective analysis of practice care delivery measures before and after adoption of R‐SC at Memorial Sloan Kettering Cancer Center (MSKCC). Data for patients (pts) with FL, DLBCL, or CLL receiving R‐based therapy from September 2016 to September 2018 were extracted from the electronic medical record. A linear mixed effect multivariate model with random intercept was used to analyze the association between treatment type (R‐IV vs R‐SC) and chair time (defined as the difference in pt room‐in and room‐out times) in the year prior to and following R‐SC adoption at MSKCC. Model covariates included treatment time and location, therapy type (monotherapy vs combination), and pt demographics. Given the prolonged infusion time, patients’ first dose of R‐IV was excluded from the analysis. Results: Data were collected during 6744 visits (3018 visits prior to R‐SC adoption and 3726 after) for 1503 pts receiving R. Pts receiving R‐IV combination therapy had a mean chair time of 203 minutes (min); overall, R‐SC injection reduced chair time by a mean of 92 min ( p &lt; 0.001 vs R‐IV). Monotherapy, regardless of route, reduced chair time by a mean of 30 min ( p &lt; 0.001) compared with combination therapy, and mean chair time was further reduced by 39 min ( p &lt; 0.001) for R‐SC pts receiving monotherapy. Reductions in chair time increased over time following initial adoption of R‐SC (p = 0.042), and were greater at the lymphoma‐specific site than multispecialty oncology infusion centers ( p &lt; 0.001). Summary/Conclusion: Adoption of R‐SC results in substantial time savings for both the pt and health system as measured by reduced chair time and improved pt throughput. Given increasing constraints on infusion chair space, increased utilization of R‐SC may improve practice efficiency and pt access to care.
THU0618 CLINICAL COMPARISON BETWEEN MAGNETIC RESONANCE TOMOGRAPHY AND X-RAY IN DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS
Authors: Marufjon Salokhiddinov, Muborak Salaeva
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> For decades, X-ray images have been used to help detect rheumatoid arthritis (RA) and to monitor for the progression of bone damage. In early RA, however, X-rays may appear normal although the disease is active – making the films useful as a baseline but not much help in getting a timely diagnosis and treatment. Modern imaging techniques, including ultrasound and magnetic resonance imaging (MRI), which can reveal early, non-bony signs of RA that are invisible on X-ray <h3>Objectives</h3> To conduct a comparative analysis of the possibility of MRI in RA patients in the early diagnosis of the disease with the data X-ray of hands and feet <h3>Methods</h3> The study included 56 patients with a reliable diagnosis of RA aged from 17 to 66 years, with disease duration from 4 months to 1 year. Verification of the diagnosis of RA was carried out in accordance with the diagnostic APA criteria (1987). The criteria for the selection of patients was the presence of disease activity. Patients were mainly with the II degree of disease activity. All patients underwent radiography of the small joints of the hands and feet, and 28 patients underwent MRI with dominant hands <h3>Results</h3> The study showed certain changes in the structures of the joint based on MRI in the early stages of RA. So, according to MRI of the brushes, it was revealed: thickening of the synovial membrane - in 23 (86%) patients; marginal erosion and subchondral cysts - in 21 (75%) patients; bone erosions - in 25 (90%) patients; phenomena of destruction of the articular cartilage (thinning, ulceration and destruction) - in 16 (57%) patients; effusion to the joints - in 19 (68%) patients and tenosynovitis - in 18 (64%) patients. In turn, the radiological data of the hands and feet showed that erosive arthritis was found in 23 (41%) patients and marginal erosions - in 22 (39%) patients <h3>Conclusion</h3> Thus, MRI of the hands plays an important role in the early diagnosis of RA, since it allows visualizing the characteristic changes in all joint structures in RA. MRI is a highly effective diagnostic method in diagnosis of RA, which in combination with other methods of research helps to establish the diagnosis at an early stage diseases and timely appointment of adequate basic treatment unlike radiography <h3>References</h3> [1] Klarlund M, Ostergaard M, Jensen KE, Madsen JL, Skjodt H, Lorenzen I. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis—the TIRA group. Ann Rheum Dis2000; 59:521 –528 [2] McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis1998; 57:350 –356 <h3>Disclosure of Interests</h3> None declared
AB1192 CLINICAL APPLICATION OF 18F-FDG PET/CT IN RHEUMATIC DISEASES
Authors: Hua Zhong
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> <sup>18</sup>F-Flurodeoxyglucose Positron Emission Tomography/Computed Tomography (<sup>18</sup>F-FDG PET/CT) is widely used in diagosing malignant diseases. It is also useful applying to autoimmune diseases. <h3>Objectives</h3> To investigate the clinical application and significance of <sup>18</sup>F-Flurodeoxyglucose Positron Emission Tomography/Computed Tomography (<sup>18</sup>F-FDG PET/CT) in rheumatic diseases. <h3>Methods</h3> Patients who underwent <sup>18</sup>F-FDG PET/CT in the Department of Rheumatology and Immunology, Peking University People's Hospital from January 2012 to July 2018 were retrospectively analyzed for clinical application and imaging characteristics of <sup>18</sup>F-FDG PET/CT in rheumatic diseases. <h3>Results</h3> 1. From 2012 to 2018, 459 patients underwent <sup>18</sup>F-FDG PET/CT examination in the Department of Rheumatology and Immunology, accounting for 5.79% of the total number of PET/CT examinations in the hospital. Further analysis of 415 patients with complete data, including 158 males (38.07%) and 257 females (61.93%), male to female ratio of 1:1.6, average age of patients are (57 ± 16.2) years old. The highest proportion group of patients is from 45 to 65 years old (201/415, 48.43%). The total number of PET-CT examinations in the whole hospital increased year by year. Compared with 2012, the number has increased nearly 10 times in 2017 among patients in the Department of Rheumatology and Immunology. 2. In patients with rheumatic diseases, major purpose of PET/CT examination included exclusion of tumors, diagnosis, and assessment of the disease activity. 3. Of all the 459 patients, 315 cases may indicate the differential diagnosis of the disease, of which 269 (85.4%) were highly suggestive of rheumatic clinical diagnosis, including 55 cases of vasculitis (17.46%), 54 cases of myositis (17.14%), 34 cases of rheumatoid arthritis (10.79%), 30 cases of Sjogren's syndrome (9.52%), 27 cases of adult still's disease (8.57%), 25 cases of systemic lupus erythematosus (7.94%), 25 cases of IgG4-related diseases (7.94%), 10 cases of rheumatic polymyalgia (3.17%) and 6 cases of systemic sclerosis (1.9%); the remaining 46 cases (14.6%) only suggested the possibility of autoimmune diseases. <h3>Conclusion</h3> Rheumatic diseases are complex and diverse, and it is difficult to diagnose. The application of <sup>18</sup>F-FDG PET/CT in the diagnosis of diseases is increasingly widespread. The results of this study suggest that <sup>18</sup>F-FDG PET/CT to some extent has significance in the classification and diagnosis of rheumatic diseases, especially for the exclusion of malignant tumors. <h3>Disclosure of Interests</h3> None declared
AB0747 RESPONSE TO SECUKINUMAB AMONG NAIVE AND BIOLOGICALLY EXPERIENCED PATIENTSIN PSORIATIC ARTHRITIS
Authors: Shehla Farrukh, Ann O. Riordan, Muhammad Haroon, Fahd Adeeb
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Secukinumab is a recombinant human monoclonal immunoglobulin IgG antibody that selectively targets IL-17A and blocks its interaction with the IL-17 receptor. Inhibition of the downstream effects of this proinflammatory cytokine thereby interferes with key psoriasis disease pathways while promoting normalization of immune function and skin histology. <h3>Objectives</h3> The aim of the study was two-fold; firstly, to compare the response to Secukinumab in psoriatic arthritis (PsA) patients who were biologically naive and experienced, and secondly to compare the response between smokers and non-smokers. <h3>Methods</h3> In collaboration with the National Psoriatic arthritis Registry of Ireland, patients who were diagnosed and treated as PsA at University Hospital Kerry between March 2017 and October 2018 were included in this population-based cohort study.Patients demographic, clinical characteristics, treatment strategies (including response rates and adverse effects) were captured at baseline and at follow-up outpatient visits. <h3>Results</h3> A total of 96 patients were identified and included in the study (mean age of 56.6 years; male to female ratio of 1:1, 49 males, 47 females). Of these patients, 15 received Secukinumab (7 biologically-naive patients, 8 patients with previous treatment failure to anti-TNF agents (3 patients received one anti-TNF, 5 received two different anti-TNFs). In the biologically-naive group, 5 patients(71%) had completeresponse to Secukinumab, one patient (14.3%) had complete improvement of joint symptoms but remained fatigued (high BRAF score) while 1 patient (14.3%) had no improvement. All 7 of these patients were exposed to cigarette smoking (6 current smokers, one ex-smoker). In patients who previously failed anti-TNF, five(62.5%) remained symptomatic (tender &amp; swollen joints, PROMs and BRAF score remained high) despite treatment with Secukinumab. Only three patients (37.5%) responded well to treatment. Two of the eight patients never smoked (both did not respond to Secukinumab) while the other 6 patients (3 responded, 3 had no response) were ex-smokers. <h3>Conclusion</h3> In our study, Secukinumab demonstrated better response to the biologically-naive PsA patients, while smoking did not increase the risk of disease activity among PsA patients receiving Secukinumab. <h3>Disclosure of interests</h3> None declared
SCoPE-MS: mass spectrometry of single mammalian cells quantifies proteome heterogeneity during cell differentiation
Authors: Bogdan Budnik, Ezra Levy, Guillaume Harmange, Nikolai Slavov
Journal: Genome biology (2018)

Some exciting biological questions require quantifying thousands of proteins in single cells. To achieve this goal, we develop Single Cell ProtEomics by Mass Spectrometry (SCoPE-MS) and validate its ability to identify distinct human cancer cell types based on their proteomes. We use SCoPE-MS to quantify over a thousand proteins in differentiating mouse embryonic stem cells. The single-cell proteomes enable us to deconstruct cell populations and infer protein abundance relationships. Comparison between single-cell proteomes and transcriptomes indicates coordinated mRNA and protein covariation, yet many genes exhibit functionally concerted and distinct regulatory patterns at the mRNA and the protein level.
Abstract 14647: Developing a Novel Vascularized 3d Cardiac Spheroid Culture to Study Interactions of Cardiomyocytes, Fibroblasts and Endothelial Cells
Authors: Julian U Wagner, Duc Minh Pham, Stefanie Dimmeler, Jaya Krishnan
Journal: Circulation (2018)

In living organs, cells exist in a 3D environment with intricate cell-cell and cell-matrix interactions. To date, in vitro experiments have been exploited to mimic in vivo situations mainly by usin...
PS1050 MARKER CHROMOSOME IS A STRONG POOR PROGNOSIS FACTOR AFTER ALLOGENEIC HSCT FOR AML PATIENTS
Authors: K. Fuse, T. Tanaka, S. Uemura, S. Tamura, T. Suwabe, T. Katagiri, T. Ushiki, Y. Shibasaki, N. Satou, T. Yano, T. Kuroha, S. Hashimoto, T. Furukawa, M. Narita, H. Sone, M. Masuko
Journal: HemaSphere (2019)

Background: Acute myeloid leukemia (AML) is the commonest type of acute leukemias in adults resulting from clonal proliferation of bone marrow precursor cells with disruption of hemostasis. Patients initially respond to induction therapy but the majority of patients suffer relapse and refractoriness with very poor subsequent prognosis. Aims: To compare two widely used salvage regimens in treatment of relapsed/refractory AML, HAM (cytarabine, Mitoxantrone, Colony stimulating factor) versus FLAG (cytarabine, fludarabine, Colony stimulating factor) protocols. Methods: Prospective randomized study included 90 patient diagnosed as relapsed/refractory AML were selected from Oncology Center, Mansoura University, Egypt, from January 2014 to December 2017. Patients received salvage therapy either HAM or FLAG protocol, then outcomes regarding to efficacy, side effects and overall survival were assessed. Results: Ninety patients were included in our study, 43 patients received HAM protocol versus 47 received FLAG protocol. Complete remission (CR) was 42.6% in HAM group versus 48.8% in FLAG group (p = 0.5). On the other hand, hepatic impairment was 46.8% in HAM group versus 30.3% in FLAG group (p = 0.2). Also, renal impairment was 6.4% in HAM group versus 18.6% in FLAG group (p = 0.07). In addition, Event free survival (EFS) was higher in FLAG vs. HAM arms (9 versus 4 months, p = 0.2). Lastly, overall survival (OS) in HAM group was shorter than in FLAG group (3 vs. 5 months, P = 0.09) Summary/Conclusion: Both HAM and FLAG protocols are adequate salvage chemotherapy in relapsed/refractory AML, with different toxicity profile as HAM has more hepatotoxicity while FLAG is more nephrotoxic, CR was slightly higher with FLAG with more survival benefit compared with HAM protocol.